Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Endocrine 5Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1754Urinary Bladder Neoplasms 351Carcinoma, Renal Cell 217Breast Neoplasms 210Neoplasms 164Kidney Neoplasms 158Lung Neoplasms 101Colorectal Neoplasms 95Motor Activity 85Testicular Neoplasms 60Ovarian Neoplasms 53Colonic Neoplasms 48Melanoma 47Pancreatic Neoplasms 44Neoplasm Metastasis 43Non-Muscle Invasive Bladder Neoplasms 42Urinary Incontinence 40Head and Neck Neoplasms 40Carcinoma, Transitional Cell 40Uterine Cervical Neoplasms 39Disease 39Sarcoma 37Urologic Neoplasms 36Recurrence 35Anxiety Disorders 32Stomach Neoplasms 29Carcinoma, Non-Small-Cell Lung 29Lymphoma 28Endometrial Neoplasms 28Prostatic Hyperplasia 27

Interventions

Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Adenoma, Islet Cell × Genitourinary × Clear all
NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡